Addressing social media debates over the scientific validity of Temple’s eponymous brain-monitoring wearable, founder Deepinder Goyal issued a statement directed at “Concerned Indian Doctors”, asserting confidence in the R&D behind the wearables.

Goyal pointed out that Temple had already spent $30 Mn on its development, including $20 Mn of his personal money. He also noted that the company is raising funding from its employees and customers. 

“Selling a few thousand devices recovers a small fraction of this investment. A scam that pays nothing is not a scam anyone would run,”  the CEO wrote in his post. 

Goyal further said the product’s 14-day no-questions-asked return policy would validate its product in the market. 

On questions over Temple’s credibility and scientific validation, he argued that many wearable makers initially relied on internal studies before publishing external validation. He said the company would release pre-prints before peer-reviewed publications and it expects independent studies to emerge once the device becomes available more widely. 

In a follow-up post, Goyal also said, “Temple is a fitness tracker, and wellness device. We are not a medical device,” adding that the device hasn’t been clinically validated. 

Important to highlight that pre-orders for the wearable officially opened on November 1, with a hefty listing price of ₹85,000.  Units are hand-made to order and expected to begin shipping roughly three months after purchase, starting in early 2027.

For context, several medical experts had criticised Temple over its claim that a wearable sensor placed near the temple can reliably measure cerebral blood flow.

Source link